Azacytidine for the treatment of myelodysplastic syndromes in the elderly

Advances in Therapy

Volumn 28, Issue SUPPL. 2, 2011, Pages 10-15

  Campelo, Maria Diez ^a   Delgado, Regina Garcia ^b   Molias, Ana Cristina Godoy ^c   Sanchez, Jesus Feliu ^d  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL SAN PEDRO   (Spain)

Author keywords

5 Azacytidine; Elderly; Myelodysplastic syndromes

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIVITAMIN K; AZACITIDINE; DEFEROXAMINE; DIURETIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IRON CHELATING AGENT;

AGED; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; CYTOPENIA; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG WITHDRAWAL; ELDERLY CARE; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; HEART FAILURE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PNEUMONIA; SURVIVAL TIME; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

AGE FACTORS; AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOOD COMPONENT TRANSFUSION; BONE MARROW; BONE MARROW EXAMINATION; HUMANS; LIFE EXPECTANCY; MALE; MONITORING, PHYSIOLOGIC; MYELODYSPLASTIC SYNDROMES; PANCYTOPENIA; TREATMENT OUTCOME;

EID: 79959732679     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0097-3     Document Type: Article

References (17)

1. Lee JS, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006;295:801-808. (Pubitemid 43244307)
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199. (Pubitemid 12073508)
3. The International Agency for Research on Cancer. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon: IARC Press; 2008.
4. Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. (Pubitemid 27132124)
5. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503-3510. (Pubitemid 47315575)
6. Park MJ, Kim HJ, Kim SH, et al. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol. 2008;81:364-373.
7. Hasse D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87:515-526.
8. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465. (Pubitemid 44511560)
9. Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997-2004. (Pubitemid 35001229)
10. Aul C, Gatterman N, Schneider W. Age related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358-367.
11. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukaemia group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
12. Kantarijan H, O'Brien S, Ravandi F. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351-1361.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. (Pubitemid 13149996)
14. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
15. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol. 2010;76:218-227.
16. Santini V, Fenaux P, Mufti GJ. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacytidine. Eur J Haematol. 2010;85:130-138.
17. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903. (Pubitemid 46630737)